About Oxurion
Oxurion is a biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has engineered a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
Oxurion owns the global rights to Jetrea (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
Oxurion is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol OXUR.
Facts about Oxurion
Facts about Oxurion
- Focus : Manufacturer
- Industry : Pharma
